Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

PFIZER INC
Mes dernières consult.
Most popular
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Pfizer Inc. : Study Shows Positive Results for Pfizer's Lyrica Treatment for Fibromyalgia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/19/2012 | 02:40pm CEST
   By Saabira Chaudhuri 
 

Pfizer Inc. (>> Pfizer Inc.) said results of a late-stage study of its pregabalin controlled-release formulation as a treatment for fibromyalgia were positive.

The drug company said top-line results of a Phase 3 study evaluating pregabalin controlled-release formulation, also known as Lyrica, in patients with fibromyalgia indicated that it had a statistically significant positive effect compared with a placebo with regards to time to loss of therapeutic response.

Pfizer described fibromyalgia as a common pain condition in the U.S. affecting more than five million Americans and characterized by chronic widespread pain and tenderness lasting for three or more months.

The most recent study is the second of three Phase 3 studies of the pregabalin controlled-release formulation, which Pfizer said will determine the potential use of pregabalin as a once-a-day therapy.

Last week, Pfizer had revealed that a Phase 3 study showed Lyrica as a potential epilepsy treatment didn't meet the primary endpoint for a change in seizure frequency. Monday, the drug company noted that the final study in post-herpetic neuralgia is ongoing.

"Collectively, the results of these controlled-release studies will allow us to better understand the potential of a once-a-day pregabalin treatment regimen," said Steven J. Romano, head of Pfizer's Global Primary Care Business Unit's Medicines Development Group. "Reducing the number of times patients need to take their medicine per day while maintaining the same efficacy and safety profile could potentially provide a greater convenience and the potential to enhance treatment adherence and outcomes."

Shares edged up 12 cents to $23.98 in recent premarket trading. The stock has risen 22% in the past year.

Write to Saabira Chaudhuri at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
01:11p PFIZER`S FAST-GROWING IBRANCE ROMPS : analyst
09/22 PFIZER : LabCentral to Open Next-Stage Facility for Growing Life Science Compani..
09/22 PFIZER : sues J&J over Remicade contracts
09/22 PFIZER : hits a snag in bid to jump-start Sutent`s flagging kidney cancer sales
09/21 PFIZER : New Immunoglobulins Study Findings Have Been Reported by Researchers at..
09/21 TRANSGENE : First Half-Year 2017 in Line with Our Objectives: All Clinical Progr..
09/21 PFIZER : National Sickle Cell Disease Poll of African Americans Dispels Long-Hel..
09/21 PFIZER : New Global Report Finds Majority of People at High Risk of Stroke Not B..
09/21 PFIZER : Phosplatin Therapeutics Announces Collaboration with Pfizer and Merck K..
09/21 PFIZER : National Sickle Cell Disease Poll of African Americans Dispels Long-Hel..
More news
News from SeekingAlpha
2015 Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update
2015 Antibiotics Stocks To Benefit From 21st Century Cures Act
2015 ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case
2015 DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb
2015 Pfizer's GL-2045 an Orphan Drug for CIDP
Financials ($)
Sales 2017 52 717 M
EBIT 2017 19 912 M
Net income 2017 11 415 M
Debt 2017 23 788 M
Yield 2017 3,57%
P/E ratio 2017 19,16
P/E ratio 2018 16,62
EV / Sales 2017 4,51x
EV / Sales 2018 4,34x
Capitalization 214 B
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 37,9 $
Spread / Average Target 5,3%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC214 146
JOHNSON & JOHNSON15.63%352 651
NOVARTIS11.88%224 990
ROCHE HOLDING LTD.6.19%220 358
PFIZER10.81%214 146
MERCK AND COMPANY11.75%177 633